This commentary reviews the risk of suicide in antidepressant drug trials. The ability of researchers to safely conduct therapeutic trials is discussed. The authors assert that it is now timely to consider ethical means of assessing suicidal risk as an explicit effect of treatment interventions in mood disorders. (35 refs.)